INVESTIGATION OF GADOLINIUM CONTRAST AGENT TOXICITY BY XAS
XAS 研究钆造影剂毒性
基本信息
- 批准号:7954477
- 负责人:
- 金额:$ 0.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-03-01 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdultAdverse effectsAutopsyBiologicalBurn injuryChildComplexComputer Retrieval of Information on Scientific Projects DatabaseContrast MediaDataEnvironmentEuropeFibrosisFunctional disorderFundingGadoliniumGrantHeadacheHeartImageInorganic SulfatesInstitutionIntravenousInvestigationJapanKidneyLeadMagnetic Resonance ImagingMedicalModelingMolecularNauseaPatientsPropertyResearchResearch PersonnelResourcesSamplingSolutionsSourceSurveysTissuesToxic effectTranslational ResearchUnited StatesUnited States National Institutes of HealthUnspecified or Sulfate Ion Sulfatesbasehuman subjectinorganic phosphateoxidationstructural biologysynchrotron radiation
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Because of their paramagnetic properties, solutions of organic gadolinium complexes and gadolinium compounds are used as intravenous radiocontrast agents to enhance images in medical magnetic resonance imaging. Gadolinium has been used for years in adults and children in the United States, Europe and Japan, without any serious complications in thousands of patients. The FDA declared Gadolinium safe for use in MRI in 1988. However, a few side effects, such as mild headache, nausea and local burning can occur. Caravan and colleagues have recently found that patients with severe kidney dysfunction are susceptible to "nephrogenic systemic fibrosis" if they get gadolinium based MR contrast. Their results indicate that in human subjects, Gd is particularly rich in the kidney and heart. A fundamental understanding of how Gd interacts with these tissues will be crucial in determining the molecular origin of Gd toxicity in these patients. We believe that surveying Gd in regions of heart and kidney tissue using XANES and EXAFS is the most appropriate first step in this unique experimental opportunity, which could potentially have a large impact on translational research. We wish to determine the local coordination environment of Gd in tissue from autopsy samples and compare these results to likely biological Gd models, such as Gd phosphate, Gd sulfate, and the organic Gd contrast agent. From these data, we will be able to clearly determine if and how the Gd contrast agent is chemically altered in kidney and heart tissue. Changes in Gd coordination and/or oxidation state could potentially lead to the adverse effects observed in the Caravan lab.
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
由于它们的顺磁性质,有机钆络合物和钆化合物的溶液被用作静脉内放射性造影剂以增强医学磁共振成像中的图像。 钆已在美国、欧洲和日本的成人和儿童中使用多年,数千名患者没有出现任何严重并发症。FDA在1988年宣布钆可安全用于MRI。然而,可能会出现一些副作用,如轻度头痛、恶心和局部烧灼感。 Caravan及其同事最近发现,严重肾功能不全的患者如果使用钆基MR造影剂,则易患“肾源性全身性纤维化”。 他们的结果表明,在人类受试者中,Gd在肾脏和心脏中特别丰富。Gd如何与这些组织相互作用的基本理解将是至关重要的,在确定这些患者中的Gd毒性的分子起源。我们认为,使用XANES和EXAFS测量心脏和肾脏组织区域中的Gd是这个独特实验机会中最合适的第一步,这可能对转化研究产生巨大影响。 我们希望从尸检样本中确定Gd在组织中的局部配位环境,并将这些结果与可能的生物Gd模型(如Gd磷酸盐、Gd硫酸盐和有机Gd造影剂)进行比较。 根据这些数据,我们将能够清楚地确定Gd造影剂在肾脏和心脏组织中是否以及如何发生化学变化。 Gd配位和/或氧化态的变化可能导致在Caravan实验室中观察到的不良反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Samuel Pazicni其他文献
Samuel Pazicni的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Samuel Pazicni', 18)}}的其他基金
INVESTIGATION OF GADOLINIUM CONTRAST AGENT TOXICITY BY X-RAY FLUORESCENCE MICROS
X射线荧光显微镜研究钆造影剂毒性
- 批准号:
7954524 - 财政年份:2009
- 资助金额:
$ 0.08万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 0.08万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 0.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 0.08万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 0.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 0.08万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 0.08万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 0.08万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 0.08万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 0.08万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 0.08万 - 项目类别:
Discovery Grants Program - Individual